<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720599</url>
  </required_header>
  <id_info>
    <org_study_id>ECT2020-002</org_study_id>
    <nct_id>NCT04720599</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy</brief_title>
  <official_title>Clinical Evaluation of ExoDx™ Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exosome Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exosome Diagnostics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study described here is being conducted to prospectively confirm the performance of the&#xD;
      ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy&#xD;
      and support of CE-marking the test for a European Union Launch.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in an initial biopsy patient cohort.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">120</enrollment>
  <condition>Urologic Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ExoDx Prostate(IntelliScore)</intervention_name>
    <description>The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer</description>
    <other_name>EPI</other_name>
    <other_name>EPI-CE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - Men, aged 50yrs or older with an elevated PSA between 2-10ng/ml scheduled for an initial&#xD;
        biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical suspicion for prostate cancer&#xD;
&#xD;
          -  Elevated Prostate-specific Antigen between 2.0-10 ng/ mL&#xD;
&#xD;
          -  Scheduled for a initial prostate biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical symptoms of urinary tract infection (including prostatitis) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  History of prostate cancer.&#xD;
&#xD;
          -  History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary&#xD;
             track symptoms within 6 months of study enrollment.&#xD;
&#xD;
          -  Known hepatitis status (all types) and/or HIV documented in patient's medical record.&#xD;
&#xD;
          -  Patients with history of concurrent renal/bladder tumors.&#xD;
&#xD;
          -  Prior MRI used in the decision to biopsy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants with prostates</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Noerholm</last_name>
    <role>Study Director</role>
    <affiliation>Exosome Diagnostics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exosome</keyword>
  <keyword>ExoDx Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD can be shared on an individual basis. Please reach out for more information.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>12 months after trial completion</ipd_time_frame>
    <ipd_access_criteria>Individual basis upon mutual agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

